ARISTOTLE "heart-failure substudy" sees apixaban stroke protection regardless ... TheHeart.Org The trial's AF patients with heart failure, LV systolic dysfunction, or both "had worse outcomes than patients with atrial fibrillation and neither heart failure nor systolic dysfunction, although this was primarily driven by mortality and not by ... |
